Etretinate (Ro 10-9359) is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. It activates retinoid receptors, causing an induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.

K03861通过与激活环素的结合位点竞争，抑制CDK2活性。[1]

在为期28天的实验中，与对照组相比，接受etretinate治疗的小鼠组的平均皮肤厚度显著降低（P < 0.05），胶原纤维束出现变化。TUNEL实验显示，接受etretinate处理14天的小鼠真皮层内TUNEL阳性细胞密度显著增加（P < 0.05）。Etretinate处理的小鼠在1天时期内procollagen α1（I）链与β actin mRNA的比例与对照小鼠相比显著降低，但在14天时期内该比例显著增加（P < 0.05）[2]。Etretinate通过诱导凋亡并可能调节细胞因子表达，在MRL/lpr小鼠中减少皮肤厚度并抑制皮肤病变的出现[3]。

The HSC-5 cells are plated in 96-well plates at a density of 1.5×103 per 100 μL and used for experiments. Preliminary experiments are performed to determine the effective dose and cytotoxicity of etretinate. The cells are incubated for 72 h with etretinate at concentrations of 5, 10, 25 and 50 nmol⁄L [dissolved in saline containing 0.0001% dimethyl sulfoxide (DMSO)]. The cells are then incubated for a further 2 h with or without 200 μmol⁄L ALA (Sigma). Each plate is then irradiated using a metal halide lamp at doses of 10, 20, 40 and 80 J⁄cm2 (Only for Reference)